Research programme: anti-MUC1 monoclonal antibodies - Vaxil Biotherapeutics

Drug Profile

Research programme: anti-MUC1 monoclonal antibodies - Vaxil Biotherapeutics

Alternative Names: Anti-MUC1 SP vaccine companion diagnostic - Vaxil Biotherapeutics; Anti-MUC1 therapeutic cancer vaccine companion diagnostic - Vaxil BioTherapeutics; ImMucin™ companion diagnostic - Vaxil BioTherapeutics; MUC1 companion diagnostic - Vaxil BioTherapeutics; SPmAb 2.1; SPmAb 6

Latest Information Update: 20 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxil BioTherapeutics
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Jun 2016 Vaxil receives patent allowance for VaxHit™ in European Union
  • 19 Jan 2014 Preclinical trials in Cancer in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top